Treatment Continuation and Long-Term Outcomes of Perampanel in Primary Orthostatic Tremor; A Cohort Study.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	Treatment Continuation and Long-Term Outcomes of Perampanel in Primary Orthostatic Tremor; A Cohort Study.
Συγγραφείς:	Babeliowsky WA; Department of Neurology and Clinical Neurophysiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Swinnen B; Department of Neurology and Clinical Neurophysiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Department of Neurology, University Hospitals Leuven, Leuven, Belgium., Hoogland J; Department Epidemiology and Data Science, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., de Bie RMA; Department of Neurology and Clinical Neurophysiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands., van Rootselaar AF; Department of Neurology and Clinical Neurophysiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.
Πηγή:	Movement disorders clinical practice [Mov Disord Clin Pract] 2026 Sep; Vol. 13 (9), pp. 2145-2153. Date of Electronic Publication: 2026 Mar 26.
Τύπος έκδοσης:	Journal Article; Observational Study; Research Support, Non-U.S. Gov't
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Wiley Country of Publication: United States NLM ID: 101630279 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2330-1619 (Electronic) Linking ISSN: 23301619 NLM ISO Abbreviation: Mov Disord Clin Pract Subsets: MEDLINE
Imprint Name(s):	Original Publication: Hoboken, NJ : Wiley, [2014]-
Ιατρικοί όροι (MeSH):	Nitriles/therapeutic use , Pyridones/therapeutic use , Dizziness/drug therapy , Tremor/drug therapy , Anticonvulsants*/therapeutic use, Humans ; Male ; Female ; Middle Aged ; Aged ; Treatment Outcome ; Prospective Studies ; Cohort Studies ; Longitudinal Studies ; Activities of Daily Living
Περίληψη:	Background: Primary orthostatic tremor (POT) is a rare hyperkinetic movement disorder with limited and largely ineffective treatment options. Perampanel has been suggested as a therapy, but has so far only been investigated in small studies with short duration. Objective: To (1) describe longitudinal perampanel use and its association with key clinical outcomes and baseline characteristics in a well-defined cohort of POT, and (2) evaluate factors possibly associated with treatment continuation. Methods: A prospective observational cohort study in POT patients who started perampanel treatment between November 2018 and November 2022, and who completed five self-report scales prior to treatment start and during clinical follow-up were included. Scales assessed daily functioning and well-being, and included the Dutch OT-questionnaire, Hospital Anxiety and Depression Scale, (instrumental) Activities of Daily Living, and the Short Form-36. Results: Thirty one POT patients were included, and followed for 32 months on average. Seventeen patients continued taking perampanel, demonstrating improvements in social functioning, fewer emotional role limitations, better mental health, and reduced pain compared to those who discontinued. Fourteen patients discontinued perampanel due to lack of effect and/or adverse effects, which were also common and persistent in those who continued. Men were more likely to continue treatment. Patients who discontinued had lower baseline functioning and well-being scores than those continuing, which persisted over time. Conclusion: In around half of patients, continued use of perampanel is associated with better clinical outcomes, also on the long term, but adverse effects are common and persistent. (© 2026 The Author(s). Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.)
References:	J Neurol. 2003 Feb;250(2):212-5. (PMID: 12574953) J Psychosom Res. 2011 Aug;71(2):74-8. (PMID: 21767686) Parkinsonism Relat Disord. 2022 Sep;102:115-117. (PMID: 36027719) Pharmacol Res. 2007 Feb;55(2):81-95. (PMID: 17129734) Front Neurol. 2018 Jan 15;8:747. (PMID: 29379467) Lancet Neurol. 2012 Apr;11(4):331-40. (PMID: 22377180) Int J Behav Med. 1996;3(2):104-22. (PMID: 16250758) Neurology. 2016 Feb 2;86(5):458-64. (PMID: 26747880) Mov Disord. 2018 Jan;33(1):75-87. (PMID: 29193359) Epilepsia. 2015 Jul;56(7):e90-4. (PMID: 26096637) Mov Disord. 2005 Nov;20(11):1455-61. (PMID: 16037915) Eur Rev Med Pharmacol Sci. 2023 Jul;27(13):6027-6039. (PMID: 37458642) Epilepsy Behav. 2022 Nov;136:108885. (PMID: 36150304) J Parkinsons Dis. 2016 Oct 19;6(4):685-698. (PMID: 27567884) J Neurol Neurosurg Psychiatry. 2002 Jan;72(1):47-52. (PMID: 11784825) Mov Disord Clin Pract. 2020 Mar 31;7(4):399-404. (PMID: 32373656) Epilepsy Behav. 2021 Aug;121(Pt A):108069. (PMID: 34077902) Epilepsy Behav. 2021 Jun;119:107965. (PMID: 33940525) Tremor Other Hyperkinet Mov (N Y). 2019 Aug 01;9:. (PMID: 31413897) Clin Park Relat Disord. 2025 Apr 01;12:100318. (PMID: 40256684) Tremor Other Hyperkinet Mov (N Y). 2018 Apr 17;8:552. (PMID: 29686940) Tremor Other Hyperkinet Mov (N Y). 2025 May 07;15:22. (PMID: 40351563) Psychol Med. 1997 Sep;27(5):1065-77. (PMID: 9300512) Mov Disord Clin Pract. 2022 Oct 13;10(1):74-78. (PMID: 36704076) Epilepsy Behav. 2021 Jun;119:107935. (PMID: 33930626) Mov Disord. 2004 Jul;19(7):788-795. (PMID: 15254936) Parkinsonism Relat Disord. 2019 Mar;60:171-172. (PMID: 30318448) Tremor Other Hyperkinet Mov (N Y). 2019 Oct 14;9:. (PMID: 31673479) Neurol Res Pract. 2020 Jan 29;2:3. (PMID: 33324909) Mov Disord Clin Pract. 2014 Jun 12;1(3):173-179. (PMID: 30363785)
Contributed Indexing:	Keywords: Perampanel; long‐term follow‐up; primary orthostatic tremor; quality of life; treatment effect
Substance Nomenclature:	H821664NPK (perampanel) 0 (Nitriles) 0 (Pyridones) 0 (Anticonvulsants)
SCR Disease Name:	Primary orthostatic tremor
Entry Date(s):	Date Created: 20260326 Date Completed: 20260918 Latest Revision: 20261029
Update Code:	20261029
PubMed Central ID:	PMC13339205
DOI:	10.1002/mdc3.70605
PMID:	41885046
Βάση Δεδομένων:	MEDLINE

Περιγραφή
ISSN:	2330-1619
DOI:	10.1002/mdc3.70605